{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Epileptic+Syndrome&page=2",
    "query": {
      "condition": "Pediatric Epileptic Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Epileptic+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T14:43:21.876Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04639310",
      "title": "XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy",
        "Epilepsy in Children",
        "Epilepsy; Seizure",
        "Disease",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Nervous System Diseases",
        "Epileptic Syndromes"
      ],
      "interventions": [
        {
          "name": "XEN496",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "1 Month to 6 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-03-29",
      "completion_date": "2023-05-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 11,
      "location_summary": "Orange, California • San Francisco, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639310"
    },
    {
      "nct_id": "NCT03790137",
      "title": "Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Photosensitive Epilepsy"
      ],
      "interventions": [
        {
          "name": "Fenfluramine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elizabeth Anne Thiele",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "4 Years to 25 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-05-31",
      "completion_date": "2024-07-19",
      "has_results": true,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03790137"
    },
    {
      "nct_id": "NCT04325282",
      "title": "Transcranial Magnetic Stimulation for BECTS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Benign Epilepsy With Centrotemporal Spikes",
        "Language Problems",
        "Learning Disorders"
      ],
      "interventions": [
        {
          "name": "Active rTMS",
          "type": "DEVICE"
        },
        {
          "name": "Sham rTMS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "5 Years to 18 Years"
      },
      "enrollment_count": 22,
      "start_date": "2020-10-28",
      "completion_date": "2024-03-03",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04325282"
    },
    {
      "nct_id": "NCT06213090",
      "title": "Patterns of Neurodevelopmental Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurodevelopmental Disorders",
        "Autism Spectrum Disorder",
        "Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection",
        "Pediatric Acute-Onset Neuropsychiatric Syndrome",
        "Down Syndrome",
        "Epilepsy",
        "Mitochondrial Encephalomyopathies",
        "Cerebral Folate Deficiency"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Richard Frye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2024-02-01",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06213090"
    },
    {
      "nct_id": "NCT04442295",
      "title": "An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "STK-001 - Single Ascending Doses",
          "type": "DRUG"
        },
        {
          "name": "STK-001 - Multiple Ascending Doses",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stoke Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 62,
      "start_date": "2020-06-29",
      "completion_date": "2023-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 18,
      "location_summary": "San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04442295"
    },
    {
      "nct_id": "NCT04485104",
      "title": "Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seizure in Participants With Tuberous Sclerosis Complex",
        "Seizure in Participants With Dravet Syndrome",
        "Seizure in Participants With Lennox-Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "GWP42003-P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "1 Month to 23 Months"
      },
      "enrollment_count": 3,
      "start_date": "2021-05-19",
      "completion_date": "2025-01-28",
      "has_results": true,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04485104"
    },
    {
      "nct_id": "NCT04740476",
      "title": "An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "zorevunersen (STK-001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stoke Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Months and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-01-20",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740476"
    },
    {
      "nct_id": "NCT01405053",
      "title": "Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lennox-Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "Rufinamide",
          "type": "DRUG"
        },
        {
          "name": "Any other approved Antiepileptic Drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "1 Year to 3 Years"
      },
      "enrollment_count": 37,
      "start_date": "2011-06-16",
      "completion_date": "2015-11-02",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 22,
      "location_summary": "San Diego, California • Aurora, Colorado • Washington D.C., District of Columbia + 19 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01405053"
    },
    {
      "nct_id": "NCT04062981",
      "title": "Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lennox Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "Carisbamate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SK Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-05-03",
      "completion_date": "2022-12-14",
      "has_results": false,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • Lebanon, New Hampshire • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04062981"
    },
    {
      "nct_id": "NCT05737784",
      "title": "A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SCN2A-DEE",
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "PRAX-222 - Initial Dose",
          "type": "DRUG"
        },
        {
          "name": "PRAX-222 - Initial Ascending Doses",
          "type": "DRUG"
        },
        {
          "name": "PRAX-222 - Optional Ascending Doses",
          "type": "DRUG"
        },
        {
          "name": "PRAX-222 - Fixed Doses",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Praxis Precision Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 60,
      "start_date": "2023-04-13",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-21",
      "last_synced_at": "2026-06-10T14:43:21.876Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05737784"
    }
  ]
}